findmyKOL

Lubna Zuberi, MD

Basic profile

Thomas Jefferson University

ORCIDNone on fileNPI
RegionPhiladelphia, PA · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Lubna Zuberi is an Endocrinology/Metabolic physician affiliated with Thomas Jefferson University. OpenAlex indexes 18 publications with 410 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
18publications

Distinct works indexed by OpenAlex.

410citations

Total citations across indexed works.

8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
5companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

211 S 9th St Ste 600
Philadelphia, PA 191076810

Telephone

215-955-1925

Registry record last updated 11 Nov 2019.

View the NPPES registry record

Industry payments

5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    73.1%
    GLP-1 receptor agonist27.7%
    Ozempic43%Trulicity43%Mounjaro10%Rybelsus3%
    Part D<11 patients
    Insulin Analog19.6%
    Lantus Solostar37%Novolog Flexpen17%Humalog Kwikpen U-10012%Tresiba Flextouch U-1007%Tresiba Flextouch U-2007%Insulin Lispro Kwikpen U-1006%Basaglar Kwikpen U-1005%Fiasp Flextouch4%Novolog3%Levemir Flexpen2%
    Part D<11 patients

    + 10 more classes in this area

  • Hormonal (systemic)

    18%
    l-Thyroxine12.9%
    Levothyroxine Sodium79%Synthroid21%
    Part D96 patients
    Thyroid Hormone Synthesis Inhibitor2.7%
    Methimazole100%
    Part D19 patients

    + 4 more classes in this area

  • Cardiovascular

    6.2%
    Statin3.9%
    Atorvastatin Calcium58%Rosuvastatin Calcium42%
    Part D23 patients
    Angiotensin receptor blocker (ARB)0.8%
    Losartan Potassium100%
    Part D<11 patients

    + 3 more classes in this area

Where care is delivered (Part B)8.8% facility · 91.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”